PL3283110T3 - Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) - Google Patents

Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)

Info

Publication number
PL3283110T3
PL3283110T3 PL16780800T PL16780800T PL3283110T3 PL 3283110 T3 PL3283110 T3 PL 3283110T3 PL 16780800 T PL16780800 T PL 16780800T PL 16780800 T PL16780800 T PL 16780800T PL 3283110 T3 PL3283110 T3 PL 3283110T3
Authority
PL
Poland
Prior art keywords
receptor
targeted against
antibodies targeted
against interleukin
interleukin
Prior art date
Application number
PL16780800T
Other languages
English (en)
Inventor
Peter Bowers
Andrew John Mcknight
David J. King
Marco Londei
Original Assignee
Anaptysbio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio, Inc. filed Critical Anaptysbio, Inc.
Publication of PL3283110T3 publication Critical patent/PL3283110T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16780800T 2015-04-15 2016-04-15 Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) PL3283110T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)
EP16780800.5A EP3283110B1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Publications (1)

Publication Number Publication Date
PL3283110T3 true PL3283110T3 (pl) 2022-06-27

Family

ID=57126337

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16780800T PL3283110T3 (pl) 2015-04-15 2016-04-15 Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)

Country Status (14)

Country Link
US (4) US10526410B2 (pl)
EP (2) EP3283110B1 (pl)
JP (4) JP6913026B2 (pl)
KR (1) KR102666920B1 (pl)
CN (2) CN115925932A (pl)
AU (1) AU2016248208B2 (pl)
CA (1) CA2982555A1 (pl)
DK (1) DK3283110T3 (pl)
ES (1) ES2914243T3 (pl)
MX (2) MX2017013080A (pl)
PL (1) PL3283110T3 (pl)
RU (1) RU2745898C2 (pl)
SG (1) SG11201708061TA (pl)
WO (1) WO2016168542A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3536710T1 (sl) 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
EP3400962A1 (en) * 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP2021517577A (ja) * 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
BR112020016738A2 (pt) * 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
AU2019306217B2 (en) * 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
IL286100B2 (en) * 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
CA3147020A1 (en) * 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
BR112022026999A2 (pt) * 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
EP4188441A1 (en) 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
JP2024518536A (ja) * 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
EP4370550A1 (en) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
SI3536710T1 (sl) * 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
WO2013098420A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
WO2014165115A1 (en) * 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized anti-n2 antibodies
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
JP2021517577A (ja) 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
IL286100B2 (en) 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
CN113316587B (zh) 2019-05-20 2024-03-26 南通壹宸生物医药科技有限公司 一种双特异性分子及其制备与用途

Also Published As

Publication number Publication date
US20200087408A1 (en) 2020-03-19
EP3283110A1 (en) 2018-02-21
JP2023040236A (ja) 2023-03-22
CN115925932A (zh) 2023-04-07
MX2023001791A (es) 2023-03-10
US10526410B2 (en) 2020-01-07
JP7721585B2 (ja) 2025-08-12
EP3283110A4 (en) 2019-02-27
NZ736535A (en) 2024-08-30
RU2745898C2 (ru) 2021-04-02
EP3283110B1 (en) 2022-04-20
JP6913026B2 (ja) 2021-08-04
HK1250941A1 (en) 2019-01-18
KR102666920B1 (ko) 2024-05-20
JP7212098B2 (ja) 2023-01-24
CN107847590B (zh) 2022-07-26
AU2016248208A1 (en) 2017-11-09
US20210388095A1 (en) 2021-12-16
US12391761B2 (en) 2025-08-19
MX2017013080A (es) 2018-02-09
US20260022181A1 (en) 2026-01-22
RU2017139481A (ru) 2019-05-15
CA2982555A1 (en) 2016-10-20
HK1252009A1 (zh) 2019-05-10
EP4176900A1 (en) 2023-05-10
US20180094065A1 (en) 2018-04-05
US11130814B2 (en) 2021-09-28
SG11201708061TA (en) 2017-10-30
AU2016248208B2 (en) 2022-03-24
KR20180002687A (ko) 2018-01-08
ES2914243T3 (es) 2022-06-08
WO2016168542A1 (en) 2016-10-20
JP2021118710A (ja) 2021-08-12
CN107847590A (zh) 2018-03-27
BR112017022086A2 (pt) 2018-07-03
RU2017139481A3 (pl) 2019-09-19
DK3283110T3 (da) 2022-05-23
JP2025163120A (ja) 2025-10-28
JP2018512157A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
PL3283110T3 (pl) Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
IL272227A (en) Anti-tigit antibodies
IL269405A (en) Anti-sirp alpha antibodies
IL272274A (en) B7-h4 antibodies and methods of use thereof
IL269002A (en) Antibodies against pd-l1
IL263834A (en) Anti-pd-l1 antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
HUE060019T2 (hu) Anti-LAG3 antitestek
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
IL257798A (en) Anti-lag-3 antibodies
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
EP3319984C0 (en) TAU LINKING ANTIBODIES
PL3274366T3 (pl) Chimeryczny receptor antygenowy
DK3368060T3 (da) Glugacon-receptor-agonister
DK3350218T5 (da) Polyomavirus-neutraliserende antistoffer
IL258502A (en) Chimeric antigen receptors targeted to psca
EP3596108A4 (en) TARGETED IMMUNOTOLERANCE
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3319983C0 (en) TAU LINKING ANTIBODIES
IL256099A (en) Antibody
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3720871A4 (en) TARGETED IMMUNOTOLERANCE